Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FLIPPER: Palbociclib + Fulvestrant in Advanced Breast Cancer
NCT02690480Phase 2Unknown
- Sponsor
- GEICAM
- Start
- Feb 2016
- Primary completion
- Jan 2020
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial in breast cancer comparing Palbociclib + Fulvestrant with Placebo + Fulvestrant (2 arms). Primary endpoint: Progression-Free Survival rate at 1 year. Status: unknown.
02
Drugs
palbociclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02690480.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02690480.